Background
Strategies to mitigate the impact of COVID‐19 in special populations are complex and challenging. Few studies have addressed the impact of COVID‐19 on pediatric patients with cancer in low‐ and middle‐income countries.
Methods
Multicenter observational cohort study with prospective records and retrospective analyses starting in April 2020 in 21 pediatric oncology centers distributed throughout Brazil. Participants: Patients under 18 years of age who are infected by the SARS‐CoV‐2 virus (confirmed diagnosis through reverse transcriptase‐polymerase chain reaction [RT‐PCR]) while under treatment at pediatric oncology centers. The variables of interest included clinical symptoms, diagnostic and therapeutic measures. The repercussions of SARS‐CoV‐2 infection on cancer treatment and general prognosis were monitored.
Results
One hundred seventy‐nine patients were included (median age 6 [4–13] years, 58% male). Of these, 55.9% had acute leukemia and 34.1% had solid tumors. The presence of SARS‐CoV‐2 was diagnosed by RT‐PCR. Various laboratory markers were analyzed, but showed no correlation with outcome. Children with low or high BMI for age had lower overall survival (71.4% and 82.6%, respectively) than those with age‐appropriate BMI (92.7%) (
p
= .007). The severity of presentation at diagnosis was significantly associated with outcome (
p
< .001). Overall mortality in the presence of infection was 12.3% (
n
= 22).
Conclusion
In children with cancer and COVID‐19, lower BMI was associated with worse prognosis. The mortality in this group of patients (12.3%) was significantly higher than that described in the pediatric population overall (∼1%).
Background/Aims: Cytogenetic and molecular genetics play a pivotal role in treatment of acute leukemias. We prospectively evaluated genetic alterations in Brazilian patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) and their association with clinical and laboratorial data.
Methods: Flow cytometry, conventional cytogenetics (CC), FISH, PCR, RT-PCR and sequencing were performed on samples from 161 de novo ALL and 155 AML.Results: Main CC findings in AML were t(15;17) (19.4%), +8 (17.4%), complex karyotype (14.6%), t(8;21) (7.6%); in ALL main CC findings were high hyperdiploidy (18.7%), low hyperdiploidy (9.7%), t(1;19) (9.7%), t(9;22) (8.2%). Frequencies of gene fusions and mutations in AML were PML-RARa 21.9%, RUNX1-RUNX1T1 7.1%, CBFB-MYH11 and MLL-AF9 2.6%, FLT3-ITD 14.2%, NPM1mut 13.6%. In ALL, ETV6-RUNX1 and BCR-ABL were present in 11.5% of the cases, TCF3-PBX1 in 10.8% and MLL-AF1 in 1.5%. Results were discordant between CC and RT-PCR in 3.6% of the cases. PML-RARa was associated with younger age, lower WBC and platelet; FLT3-ITD with higher hemoglobin and WBC; NPM1mut with higher platelet and WBC, older age and normal karyotype. BCR-ABL was associated with higher age; MLL-AF1 with higher WBC and EGIL BI-subtype.
Conclusions:The incidence of some aberrations in AML differed from international literature. Discrepancies found between methodologies reinforce the importance of both CC and PCR in the diagnosis of leukemias.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.